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Indole compounds, related to the metabolism of tryptophan, constitute an extensive family, and are
found in bacteria, plants and animals. Indolic compounds possess significant and complex physiological
roles, and especially indole alkaloids have historically constituted a class of major importance in the
development of new plant derived drugs. The indole alkaloid alstonine has been identified as the major
component of a plant-based remedy, used in Nigeria to treat mental illnesses by traditional psychiatrists.
Although it is certainlydifficult to compare the very concept of mental disorders in different cultures, the
traditional use of alstonine is remarkably compatible with its profile in experimental animals. Even
though alstonine in mice models shows a psychopharmacological profile closer to the newer atypical
antipsychotic agents, it also shows important differences and what seems to be an exclusive mechanism
of action, not entirely clarified at this point. Considering the seemingly unique mode of action of alston-
ine and that its traditional use can be viewed as indicative of bioavailability and safety, this review
focuses on the effects of alstonine in the central nervous system, particularly on its unique profile as
an antipsychotic agent. We suggest that a thorough understanding of traditional medical concepts of
health and disease in general and traditional medical practices in particular, can lead to true innovation
in paradigms of drug action and development. Overall, the study of this unique indole alkaloid may be
considered as another example of the richness of medicinal plants and traditional medical systems in the
discovery of new prototypic drugs.
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Introduction
Indole compounds constitute an extensive family of com-
pounds found in bacteria, plants and animals (1); in general,
these compounds are related to the metabolism of tryptophan
and present substitutions in different positions of the indole
ring (2). Indolic compounds with significant and complex
physiological roles include those related to melatonin and
serotonin (5-hydroxytryptamine). Indole alkaloids possess an
indole ring in its structure, constituting a versatile heterocyclic
discovery in 1866 (1); this extensive group of alkaloids
received more attention after the isolation of reserpine
from Rauwolfia serpentina Benth., an alkaloid that changed
the history of conditions as diverse as schizophrenia and
hypertension. Indolic alkaloids include various plant-derived
medicinal products, including the well-known anti-tumor
vinblastine, vincristine, vincamin and camptothecin isolated
from Catharanthus roseus L. Don. (3).
Among the chemical classes present in medicinal plant spe-
cies, alkaloids stand as a class of major importance in the
development of new drugs because alkaloids possess a great
variety of chemical structures and have been identified as
responsible for pharmacological properties of medicinal
plants. Some plant families have the genetic capability of pro-
ducing more than one alkaloid, reflected in the structural
diversity of these compounds (3).
We have previously identified the indole alkaloid alstonine
(3,4,5,6,16,17-hexadehydro-16-(methoxycarbonyl)-19 alpha-
methyl-20 alpha-oxyhoimbanium, see Fig. 1) as the major
component of a plant-based remedy traditionally used in
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be found in various plants species: Alstonia boonei De Wild
(Apocynaceae), C. roseus (L.)G. Don (Apocynaceae),
Picralima nitida (Stapf) Th. & H. Dur (Apocynaceae),
Rauwolfia caffra Sond. (Apocynaceae) and Rauwolfia vomit-
oria Afzel. (Apocynaceae) (5). A. boonei is used in African
ethnomedicine for the treatment of malarial disease, and can
be used as astringent, antifebrile, antihelmintic, antispasmodic
among other indications (5). C. roseus has been indicated as a
purgative, to treat indigestion and dyspepsia, and has been
considered to be useful in the treatment of diabetes; neverthe-
less, the studies to verify antidiabetic properties of C. roseus
extracts led instead to the discovery and isolation of the
above mentioned complex indole alkaloids vinblastine and
vincristine (6).
R. caffra is traditionally used to treat fever, insomnia,
rheumatism and pneumonia, whereas R. vomitoria can be asso-
ciated with Xylopia aethiopica (Dun) A. Rich. (Annonaceae)
to treat convulsions in children (5); these two species possess
anti-inflammatory activity (7). The methanol extract of P.
nitida fruit showed potent and dose-dependent anti-inflamma-
tory, antipyretic and antimalarial activities (8); in addition, it
has also been indicated in the treatment of trypanosomiasis (9).
This review focuses on the effects of alstonine in the central
nervous system, particularly as an antipsychotic agent.
Ethnopharmacology of a Traditional
Antipsychotic
The study of alstonine as antipsychotic arose in the course of
an ethnopharmacological expedition (February 1993) in
Nigeria, among the Igbo people. The field research methodo-
logy involved an ethnopharmacologist–physician team con-
ducting research in collaboration with local scientists
(botanists) and local experts such as healers of various kinds.
The team was invited by a traditional leader to visit Dr C.O.,
a traditional psychiatrist who agreed to collaborate with
the project. On his grounds Dr C.O. maintains a shrine for
healing practices, part of a clinic (that includes patient sleeping
quarters), so that ‘mad’ patients can stay under his care until
restored to health. He presented a plant medicine named
‘uhuma obi-nwok’, in Igbo ‘the heart of man’. The plant is
used to treat different types of ‘madness’, epilepsy, and is in
general considered to be a sedative. To treat severe ‘madness’
the ground root is boiled in water (a piece of root about 10 cm
long and 5 cm in diameter is prepared in 250 ml of water) until
the liquid turns into a reddish-brown in color; the initial load-
ing dose for an adult is one cup. Dr C.O. reported that 1 h after
taking the medicine the person would fall asleep as long as
2–3 days; thereafter, the daily dose is half-a-cup three times
a day for 2 weeks, and subsequently the dose is tapered
down. As the dose is reduced the patient would gradually be
awake for longer periods of the day. If the patient does not pre-
sent symptoms of ‘madness’ during these alert periods the dose
is further reduced. Dr C.O. reports considerable success of this
treatment, with patients eventually being free of both medicine
and ‘madness’ symptoms.
If the patient arrives in an exceedingly agitated state, one
teaspoon of the powdered root is prepared in 20 ml Gin
(a shot) to be taken by the patient as a single dose, inducing
some 3 h of deep sleep. The roots and leaves may also be
soaked in water, and bathing with this water has sedative
effects; in fact, big pots with soaked root could be found at
the clinic in each room. The leaf sap of this same species can
also be taken orally (applied directly to the tongue) to treat
convulsions.
When asked to assist in collecting the species, Dr C.O. told
us that we would have to travel 2–3 days to get to the proper
location, and that he did not have time to take us there. Never-
theless, he gave us circa 45 g of dried root powder from his
office stash and told us to analyze it in the laboratory. A crude
ethanol extract (SP49000) was obtained from this powdered
root material and analyzed for psychopharmacological activ-
ity, particularly antipsychotic properties. SP49000 clearly
showed a neuroleptic-like activity in various mice models,
such as protection of lethality induced by amphetamine in
grouped mice (Fig. 2) and reversal of amphetamine-induced
(Fig. 3A) and apomorphine-induced (Fig. 3B) stereotypy;
additionally, the extract potentiated barbiturate-induced sleep-
ing time (Fig. 4) (4).
The chemical analysis of SP49000 revealed reserpine-like
alkaloids, alstonine being the dominant component. Possible
local sources of these alkaloids have been mentioned earlier;
R. caffra, commonly used in Igboland for medicinal purposes
(10) is a good candidate as Dr C.O. source. Dr C.O. was visited
on a couple of other occasions and demonstrated interest in the
research, but did not reveal his plant source. Dr C.O and one of
the authors (E.E.) actually exchanged amicable correspond-
ence, discussing the data and other matters.
Antipsychotic Properties of Alstonine
Schizophrenia is a neuropsychiatric disorder characterized
by diverse symptoms including hallucinations, delusional
thinking, thought disorder, attention deficit and cognitive
Figure 1. Chemical structure of indolic alkaloid alstonine.
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and once the illness begins there is rarely a full return to nor-
mal levels of functioning. Studies of the pathophysiology of
this disorder have focused on the heritability of schizophrenia,
the affected neurotransmitter systems and neuroanatomical
abnormalities (11).
Schizophrenia is associated with abnormalities of multiple
neurotransmitter systems, including dopamine, serotonin,
g-aminobutyric acid (GABA) and glutamate. Typical and
atypical antipsychotic agents differ in their receptor-binding
affinities, which are related to their differing side-effect pro-
files. Novel therapeutic strategies include normalization of
synaptic dopamine or serotonin levels, serotonin receptor
antagonism and modulation of cerebral protein synthesis (12).
In mice models alstonine shows a clear, dose-dependent
(inverted U shape), potent antipsychotic profile (13). The
increased lethality induced by amphetamine in grouped mice
is considered to be a specific model, since the lethality is
prevented by antipsychotics, but not other tranquilizers (e.g.
barbiturates and benzodiazepines). This effect is related to
the ability of antipsychotics to block D2 receptors (14).
Alstonine (i.p.) prevented amphetamine-induced lethality,
with active doses within the range of 0.5–2.0 mg kg
 1 (Fig. 5).
Ellenbroek (15) discussed the correlation of antipsychotic
agents in preventing amphetamine- and apomorphine-
induced stereotypies and their capacity to induce extrapyram-
idal symptoms in patients. Classical and atypical antipsychot-
ics have different effects on these models. Alstonine reduced
apomorphine-induced (6A) but not amphetamine-induced
(Fig. 6B) stereotypy. Interestingly enough, in this regard,
alstonine differs from the original plant extract effective
Figure 2. Effects of haloperidol (HAL), reserpine (RES), SP49000 (SP) and
respective vehicles (SAL, TWE, PEG) on amphetamine-induced lethality in
grouped mice. Drugs were administered intraperitoneally *P < 0.05, Fisher.
Figure 3. Effectsof haloperidol (HAL),SP49000(SP) andrespectivevehicles
(SAL, PEG) on amphetamine- (A) and apomorphine-induced (B) stereotypies.
Drugs were administered intraperitoneally *P < 0.05, **P < 0.01, Mann–
Whitney.
Figure 4. Potentiation of barbiturate sleeping time by diazepam (DPZ),
SP49000 (SP) and vehicles (TWE, PEG). Drugs were given intraperitoneally
**P < 0.01, ANOVA.
Figure 5. Effects of classical (haloperidol and chlorpromazine) and atypical
antipsychotics (clozapine and sulpiride), reserpine, barbiturate (pentobarbital)
and benzodiazepine (diazepam), alstonine and vehicles (saline, tween) on
amphetamine-induced lethality in grouped mice (doses in mg kg
 1). Drugs
were administered intraperitoneally *P < 0.05, Fisher.
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typy.
As can be seen at Fig. 7, similar to clozapine and sulpiride
(atypical antipsychotics) (Fig. 7B) alstonine prevents
haloperidol-induced catatonia (Fig. 7A). Several classes of
drugs can prevent haloperidol-induced catalepsy, such as
anticholinergics, D1 and D2 agonists, 5HT modulators and
glutamate NMDA antagonists (16–18).
Regarding potentiation of barbiturate-induced sleeping time,
alstonine exhibited hypnotic properties, compliant with most
antipsychotics (Fig. 8). This result is also consistent with the
emphasis on the hypnotic effects of alstonine containing plant
preparation given Dr C.O.
As the clinical effectiveness of antipsychotic drugs has been
associated with the blockade of mesolimbic D2 receptors, the
studies of antipsychotics have been centered on drugs that
modulate dopaminergic activity. However, side effects
induced by antipsychotic drugs also results from D2 receptors
blockade at the nigroestriatal system (19). A detailed under-
standing of specific roles of dopamine nuclei, projections,
receptor subtypes and the cross talk among neurotransmitter
systems have disclosed new ways of looking at the effects of
antipsychotics (20), as well as the contribution of neurotrans-
mitters other than dopamine to both schizophrenia and its
treatments. As mentioned above, alstonine was active in the
range 0.5 and 2.0 mg kg
 1 against amphetamine-induced leth-
ality, following an inverted U shape dose–effect relationship.
This pattern has not been reported for any other antipsychotic
drug; this unique pattern argues in favor of a multiple
mechanism of action, a complex interaction with more than
one neurotransmitter system.
Adding to the hypothesis of alstonine singular mechanism of
action, a neurochemical investigation revealed that alstonine
Figure 6. Effects of alstonine and vehicle (saline) on apomorphine- (A) and
amphetamine-induced (B) stereotypies (doses in mg kg
 1). Drugs were admin-
istered intraperitoneally *P < 0.05, **P < 0.01, Mann–Whitney.
Figure 7. Effectsofalstonine(A),sulpiride,clozapine(B) andvehicle(saline)
on haloperidol-induced catatonia (doses in mg kg
 1). Drugs were administered
intraperitoneally *P < 0.05, **P < 0.01, Mann–Whitney.
Figure 8. Effects of classical antipsychotics (haloperidol and chlorpromaz-
ine), atypical antipsychotics (clozapine and sulpiride), reserpine, benzo-
diazepine (diazepam), alstonine and respective vehicle (saline, tween and
PEG) on barbiturate-induced sleeping time (doses in mg kg
 1). Drugs were
administered intraperitoneally *P < 0.05, **P < 0.01, Mann–Whitney.
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placement curves of [
3H]Spiperone and [
3H]SCH23390 also
revealed lack of significant interaction of alstonine with
dopamine D1 and serotonin 5-HT2A receptors obtained from
striatum and cortex membranes, respectively (Fig. 9) (13).
Hence, although close to atypical antipsychotics in mouse
behavioral models, alstonine differs from these in the neuro-
chemical basis of its mechanism of action.
Anxiolytic Properties of Alstonine
Symptoms of anxiety are very common, and thought to accom-
pany many disorders, including schizophrenia. Antipsychotic
therapy reduces anxiety concomitant with alleviation of the
psychosis (21); in fact, a significant amount of attention has
been given to the links between anxiety and schizophrenia
(22). It has been argued that the anxiolytic property of certain
antipsychotics is a crucial feature for ameliorating the so-
called negative symptoms that affect the quality of life of
some schizophrenic patients (23–25). It has been suggested
that drug differences in relevant behavioral models presenting
may be indicative of a likewise diverse clinical profile (26).
Experimental animals demonstrate anxiety, fear and curios-
ity when placed in a new environment, and an overall assess-
ment of behavior can be determined by observing freezing,
grooming (fear) or rearing, head-dips (curiosity), and the num-
ber of fecal boluses (stress) (27–29). The ‘hole-board’ and
‘light/dark’ models are frequently used to detect and evaluate
anxiolytic/anxiogenic properties of drugs (30–34). Alstonine
clearly behaves as anxiolytic in both of these animal models
(35). In the hole-board model, alstonine significantly increases
the number of head-dips (Fig. 10A); in the light/dark test, it
significantly increases the time spent in light area exploration
(Fig. 10B) as well as the latency for first crossing from light
to dark compartment (Fig. 10C). Alstonine per se (0.5 and
1.0 mg kg
 1) neither interfered with spontaneous locomotion
(see Fig. 13A), nor induced deficits in the rota-rod test (data
not shown), indicating that at doses presenting antipsychotic
and anxiolytic properties, alstonine does not cause motor defi-
cits (35). An increase in the latency for the first crossing is con-
sidered a reliable parameter to measure the disinhibitory
behavior and decreased anxiety (36); in this case, false positive
due to sedation is ruled out by the absence of effects of alston-
ine in ambulation.
The participation of D1, 5-HT2, NMDA and GABA recept-
ors in the effects of alstonine was examined in these models,
by pretreatments with appropriate antagonists. In the hole-
board model, the increase in head-dips induced by alstonine
was not modified by previous administration of SCH23390
(D1 antagonist), MK-801 (NMDA antagonist) or picrotoxine
(GABAA antagonist), but prevented by ritanserin (5-HT2A/C
antagonist) (Fig. 11A). Alstonine also attenuated the number
of squares crossed, increased in this model by MK-801
Figure 9. Influence of alstonine on [3H]SCH23390 specific binding to stri-
atum (for D2 receptors), [3H]Spiperone specific binding to striatum (for D1
receptors) and [
3H]Spiperone specific binding to frontal cortex (for 5-HT2A
receptors).
Figure 10 Effects of alstonine, diazepam, clozapine and sulpiride in mice
models of anxiety. Alstonine (alsto, 0.5 and 1.0 mg kg
 1 i.p.), diazepam
(diaz, 2.0 mg kg
 1 i.p.), clozapine (cloza, 0.1 mg kg
 1 s.c.) and sulpiride
(sulp, 10.0 and 20.0 mg kg
 1 i.p.), or vehicles (saline or PPG) were injected
30 min prior to the behavior measurements: (A) head-dips; (B) time in the
light zone; (C) latency for the first crossing. Each column represents the
mean ± SEM. (N ¼ 10–14). **P < 0.01, *P < 0.05 versus vehicle-treated
group, ANOVA followed by Student–Newmann–Keuls.
eCAM 2006;3(1) 43(Fig. 11B). In the black and white model, the alstonine-
induced increase in the latency for first crossing (Fig. 12A)
and the time spent in the light zone (Fig. 12B) was also preven-
ted by previous administration of ritanserin (2.0 mg kg
 1).
Although data from binding assays (13) do not suggest direct
interaction of alstonine with 5HT2 receptors, the results with
the hole-board and light/dark models are indicative of the
involvement of 5-HT2A/2C receptors in the mode of action of
alstonine. The findings that 5-HT2 or 5-HT3 receptors block-
ade by ritanserin, ondansetron and other agents has a disinhib-
itory profile in animal models of anxiety (37) provided further
support for the serotonergic modulation of anxiety (38). A
serotonergic involvement with the anxiolytic profile of alston-
ine would be, therefore, not entirely surprising, and correlates
well with the previously reported disinhibitory effects of
clozapine and thioridazine (39). In fact, it has been proposed
that new agents that modulate the 5-HT2 family of serotonin
receptors could have a significant impact on mental disease
management (40,41), including anxiety, depression, schizo-
phrenia and other disorders (42).
Pharmacological studies have revealed that the blockade of
NMDA receptors in vivo causes behavioral abnormalities
accompanied by functional alteration of monoaminergic neur-
onal systems. For example, noncompetitive NMDA receptor
antagonist MK-801 or phencyclidine (PCP) induces character-
istic rodent behavioral syndromes, including hyperlocomotion
and stereotypy, which are accompanied by an increase in
dopaminergic and serotonergic neuronal activities in various
brain regions (43). MK-801-induced hyperlocomotion is
therefore used as a simple test associated with dopaminergic
alterations and considered by some as an experimental model
useful to study antipsychotics (44). Alstonine (0.1, 0.5 and
1.0 mg kg
 1) prevented MK-801 induced hyperlocomotion
(Fig. 13B). Because alstonine partially reversed MK-801-
induced increase in locomotion both at the hole-board and
locomotor activity cages, a possible role of NMDA glutamate
receptors in alstonine mechanism(s) of action should also be
considered.
The regulation of fear and anxiety is strongly associated with
the central GABA and serotonergic (5-HT) systems (28).
Recently however, other neurotransmitter systems (such as
cholinergic, dopaminergic and glutamatergic) in modulating
emotional behavior have received attention (45). It has been
Figure 11. Effect of the interaction of alstonine and antagonists in the mice
hole-board model. Animals were treated with saline or the antagonists
SCH23390 (SCH, i.p., 0.1 mg kg
 1), ritanserin (Rit, 2.0 mg kg
 1), MK-801
(MK, 0.1 mg kg
 1) and picrotoxine (Picr, 1.0 mg kg
 1) 30 min prior to vehicle
(solution saline 0.9%) or alstonine (alsto, 1.0 mg kg
 1). The test was per-
formed 30 min after the last drug administration. (A) Head-dips; (B) squares
crossed. Each column represents the mean ± SEM. (N ¼ 10–14). **P < 0.01,
*P < 0.05 versus vehicle-treated group, a ¼ P < 0.01, versus MK-801-
saline, ANOVA followed by Student–Newmann–Keuls.
Figure 12. Effect of the interaction of alstonine and ritanserin in the light/dark
model. Animals were treated with saline (sal) or the antagonist ritanserin
(Rit, 2.0 mg kg
 1) prior to saline or alstonine (alsto, 1.0 mg kg
 1). The test
was performed 30 min after the last drug administration. (A) Latency; (B)
time spent in the light zone. Each column represents the mean ± SEM.
(N ¼ 10–12) **P < 0.01 vehicle-treated group. ANOVA followed by
Student–Newmann–Keuls.
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anxiolytics (46).
Alstonine Lacks Epileptogenic Property
A serious risk of antipsychotic drugs to induce seizures is com-
monly acknowledged, and the administration of these drugs in
epileptic patients requires specific measures for a safe use (47).
The pro-convulsant property of antipsychotic has been related
to their dopamine D2-receptor blocking activity, and partially,
to their activity on histaminergic receptors (48). However, the
new antipsychotic drugs with anti-serotonergic mechanisms
changed the concept of this somehow simplistic anti-
dopaminergic hypothesis. As a matter of fact, the occurrence
of seizures with atypical agents is highest among antipsychot-
ics. Clozapine (a phenotiazine) is the most widely studied anti-
psychotic in this regard; it carries the highest seizure risk, with
an incidence of 3.5%, compared to 0.9% for olanzapine, 0.9%
for quetiapine and 0.3% for risperidone (49).
The experimental profile of alstonine showed similarities
with clozapine; it was thus of interest to verify if alstonine pos-
sessed pro-convulsant properties. The evaluation was done by
analyzing the effects of repetitive administrations of anti-
psychotic doses of alstonine. The repeated brief low-intensity
sub-convulsive focal electrical stimulation of certain brain
areas, at intervals of hours or days, resulting in a progressive
development of generalized seizures is known as ‘the Kindling
phenomenon’, originally described by Goddard et al. (49). It is
understood that the kindling-induced enhanced seizure activity
reflects a long-lasting alteration of the neuronal excitability,
suggestive of neuronal plasticity (50). Alstonine (0.5 and 1.0
mg kg
 1) did not induce kindling throughout a 30-day period,
suggesting that alstonine, unlike clozapine, lacks pro-
convulsant properties (51) (Fig. 14).
Alstonine does not affect dopamine binding in striatal mem-
branes, indicating lack of direct interaction with dopamine D1
or D2 receptors (13). The anxiolytic property of alstonine is not
antagonized by the GABAA antagonist picrotoxine (35); this
lack of GABAA modulation by alstonine may be one important
factor in its apparent lack of pro-convulsant activity. Despite
the fact that drugs acting as 5-HT2 antagonists enhanced
NMDA-mediated transmission (52), the lack of pro-
convulsant activity found with repeated alstonine administra-
tion suggests that the enhancement of NMDA transmission
produced by a possible serotonergic antagonism of alstonine
is not a significant factor for inducing seizures.
Figure 13. Effects of alstonine (alsto, 0.1, 0.5 and 1.0 mg kg
 1), clozapine
(cloza, 0.1 and 0.5 mg kg
 1), sulpiride (sulp, 10.0 and 20.0 mg kg
 1) or saline
on spontaneous locomotion (A) and MK-801-induced hyperlocomotion (B).
Each column represents the mean ± SEM. (N ¼ 10). **P < 0.01 versus
vehicle-treated group, ANOVA followed by Student–Newmann–Keuls.
Figure 14. Number of myoclonic jerks (MJs) induced by repeated administration of alstonine (0.5 and 1.0 mg kg
 1), clozapine (1.0 mg kg
 1) and saline. Data
expressed as media and standard error (SE). Observations were done in the hour following alternate days of drug administrations. N ¼ 6 mice per group.
*P < 0.5 and **P < 0.01, ANOVA/SNK.
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tex and 5HT2A/C receptors in areas of relevance to anxiety
(such as amygdala and septo-hypocampal system) (53) could
be the basis for these apparent conflicting results. It can be sug-
gested that alstonine may act restoring the appropriate levels of
excitability in areas relevant to the symptoms of schizophre-
nia, without inducing concomitant excess excitability that
results in seizures.
Alstonine and Glutamate
Despite playing important roles in diverse physiological func-
tions, the NMDA mediated glutamatergic neurotransmission
is related to various pathologies, including neurodegenerative
diseases, ischemia, epilepsy and schizophrenia (54–56). There
are several arguments in favor of a glutamate involvement in
schizophrenia. Pharmacological evidences indicate that a
glutamate hypoactivity may be associated with the disease,
more specifically in reference to NMDA-mediated glutamate
activity (57). It is believed that schizophrenia has a
neurodevelopmental component and NMDA receptors are
crucial for axonal signaling during development (58). Schizo-
phrenic patients present a marked cognitive deficit and
cognition is associated with neuronal plasticity mediated by
NMDA receptors (59). Another relevant observation is that
in schizophrenia a reduction in grey matter is verified, argu-
ably the result of NMDA-mediated neurotoxicity (60). Addi-
tionally, ketamine (an NMDA antagonist) increases the
sensibility to audio hallucinations in schizophrenics, perhaps
by accentuating a subjacent glutamatergic deficit in regions
linked to audition (61). Therefore, a variety of symptoms
found in schizophrenia could be partially explained through
an alteration of NMDA-mediated glutamatergic neurotrans-
mission (57).
As seen earlier, in mouse models alstonine (0.5–1.0 mg
kg
 1) (i.p.) reverses MK-801-induced effects (35). A prelimin-
ary neurochemical analysis indicates that alstonine does not
interfere directly with [
3H] glutamate release in cortical
synaptosomes (data not shown). If alstonine does not affect
directly NMDA receptors or glutamate release and uptake, a
possible interpretation of alstonine reversal of MK-801-
induced effects could be an indirect modulation of glutamate
transmission exerted by alstonine through the serotonin
system. It has been observed that some antipsychotics inhibit
5-HT2A serotonin receptors reducing the response to NMDA
antagonists (62,63). Such diminished response is, in turn, com-
patible with the fact that 5-HT2 antagonists increase NMDA
glutamatergic transmission (52,64).
Attuned with this interpretation is the demonstration that the
anxiolytic effects of alstonine are blocked by previous admin-
istration of ritanserine, suggesting that the anxiolityc proper-
ties of this alkaloid depend on 5-HT2A/2C serotonin receptors
(35). Interaction with 5-HT2A/2C serotonin receptors is com-
mon to other atypical antipsychotics, such as clozapine and
olanzapine (65), again illustrating the relevance of the
complex cross talk between glutamate and serotonin for
antipsychotic effects. Since there is no indication that a direct
stimulation of 5-HT2A/2C result in anxiolytic effects, and given
the blocking effect of previous administration of ritanserine, it
is tempting to speculate that alstonine may act as an inverse
agonist of 5-HT2A/2C serotonin receptors; nevertheless binding
studies are necessaryto clarify the exact mode of the anxiolytic
action of alstonine.
Other Properties of Alstonine
Alstonine has the capacity to distinguish cancer DNA from
healthy tissue DNA; it inhibits DNA in vitro synthesis when
DNA from different cancerous tissues or cells is used as tem-
plate. Practically without effects on DNA from healthy tissues,
the inhibitory effect of alstonine is due to its capacity to form
an ‘alkaloid-cancer DNA’ complex (66).
Alstonine, as well as serpentine and sempervirine, success-
fully treat a relatively important proportion of BALB/C mice
inoculated with transplantable YC8 lymphoma ascites cells
as well as Swiss mice bearing Ehrlich ascites carcinoma cells.
However, the development of some solid tumors is only par-
tially prevented by alstonine. These results illustrate the anti-
cancer activity of alstonine (67).
Wright et al. (68) studied alkaloids present in various plant
species as antimalarials. In a preliminary evaluation, extracts
of A. constricta and alstonine demonstrated in vivo antimal-
arial activity (69).
The interaction of tetrahydroalstonine, an alkaloid closely
related to alstonine, with the a-adrenergic receptors have
been reported by Demichel and Roquebert (70). Raubasine,
tetrahydroalstonine and akuammigine were shown to have
inhibitory effects on sympathetic stimulation or adrenaline-
induced hypertension, demonstrating specificity for presyn-
aptic a2-adrenergic receptors (71).
Conclusion
Alstonine is an alkaloid present in a variety of plant species
used in traditional medical systems. Biomedical examination
revealed that alstonine is bioactive, distinct in its antipsychotic
and anticancer properties.
The antipsychotic profile of alstonine is remarkably coher-
ent with its use by Nigerian traditional psychiatrists. In many
aspects the antipsychotic profile of alstonine is relevant to
the development of new antipsychotic medications:
  The traditional use of several species containing alstonine
is indicative of bioavailability;
  Although a thorough assessment would certainly be
needed, traditional use is also indicative of safety (a
relative concept in regard to all medicines);
  Although it is certainly open to debate how to compare
the very concept of mental disorders in different cultures,
the traditional use of alstonine by Nigerian traditional
psychiatrists is remarkably compatible with its profile in
experimental animals, altogether indicative of effective-
ness as antipsychotic;
46 Alstonine as an antipsychotic drug  Alstonine possesses clear anxiolytic activity, mediated by
5-HT2A/2C serotonin receptors, suggesting effectiveness
against negative symptoms of schizophrenia;
  Alstonine seems to interfere with the glutamate system in
a manner consistent with resulting beneficial effects for
schizophrenia;
  Alstonine lacks the pro-convulsant property common to
many antipsychotics, a considerable advantage for
chronic use in general and epileptic schizophrenic
patients in particular;
  The lack of direct effects on the dopaminergic system
suggests lack of significant extra pyramidal effects, the
major drawback of many antipsychotic agents.
Rauwolfia alkaloids producing species usually produce
several alkaloids, including reserpine—the first antipsychotic
medication used in modern medicine. It is worth remembering
that reserpine is the major component of R. serpentina used
to treat mental illness in India for centuries before its re-
discovery in the 20th century by the contemporary biomedical
paradigm. The various pharmacological effects of reserpine
are so prominent that it is not surprising that minor compon-
ents likely to be present in Rauwolfia spp. crude extracts/
formulations (including alkaloids like serpentine, ajmalicine
and alstonine) would have been neglected as potential key act-
ive components in earlier psychopharmacology evaluations.
Progress in psychopharmacology and neurochemistry are
constantly unveiling new cellular and molecular targets relev-
ant to drug’s mode of action; it is therefore arguable and
expected that traditional treatments (including plant-based
remedies) may act as disease modifiers by eliciting physiolo-
gical responses through mechanisms yet to be elucidated. We
suggest that a thorough understanding of traditional medical
concepts of health and disease in general and traditional med-
ical practices in particular, can lead to true innovation in para-
digms of drug action and development. In sum, the study of
this unique indole alkaloid may be considered as another
example of the wealth of medicinal plants and traditional med-
ical systems in the discovery of new prototypic drugs (72,73).
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